Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.

Hoepner R, Faissner S, Salmen A, Gold R, Chan A.

J Cent Nerv Syst Dis. 2014 Apr 28;6:41-9. doi: 10.4137/JCNSD.S14049. eCollection 2014. Review.

2.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.

N Engl J Med. 2012 May 17;366(20):1870-80. doi: 10.1056/NEJMoa1107829.

3.

Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy.

Salmen A, von Ahsen N, Trampe AK, Hoepner R, Plavina T, Subramanyam M, Kuesters G, Gold R, Chan A.

Mult Scler J Exp Transl Clin. 2016 Feb 8;2:2055217316630008. doi: 10.1177/2055217316630008. eCollection 2016 Jan-Dec.

4.

The use of natalizumab for multiple sclerosis.

Brandstadter R, Katz Sand I.

Neuropsychiatr Dis Treat. 2017 Jun 28;13:1691-1702. doi: 10.2147/NDT.S114636. eCollection 2017. Review.

5.

Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.

Perkins MR, Ryschkewitsch C, Liebner JC, Monaco MC, Himelfarb D, Ireland S, Roque A, Edward HL, Jensen PN, Remington G, Abraham T, Abraham J, Greenberg B, Kaufman C, LaGanke C, Monson NL, Xu X, Frohman E, Major EO, Douek DC.

PLoS Pathog. 2012;8(11):e1003014. doi: 10.1371/journal.ppat.1003014. Epub 2012 Nov 8.

6.

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B.

Ann Neurol. 2014 Dec;76(6):802-12. doi: 10.1002/ana.24286. Epub 2014 Oct 24.

7.

Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring.

Alroughani RA, Aref HM, Bohlega SA, Dahdaleh MP, Feki I, Al Jumah MA, Al-Kawi MZ, Koussa SF, Sahraian MA, Alsharoqi IA, Yamout BI.

BMC Neurol. 2014 Feb 12;14:27. doi: 10.1186/1471-2377-14-27. Review.

8.

Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.

Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J.

Mult Scler. 2015 Oct;21(12):1600-3. doi: 10.1177/1352458514567728. Epub 2015 Feb 6.

PMID:
25662344
9.

Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.

Schwab N, Schneider-Hohendorf T, Wiendl H.

Int Immunol. 2015 Jan;27(1):47-53. doi: 10.1093/intimm/dxu096. Epub 2014 Oct 17. Review.

PMID:
25326459
10.

Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.

Bartt RE.

Curr Opin Neurol. 2006 Aug;19(4):341-9. Review.

PMID:
16914971
11.

Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.

Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D.

JAMA Neurol. 2013 Mar 1;70(3):398-402. doi: 10.1001/jamaneurol.2013.1960. Review.

PMID:
23338729
12.

Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?

Havla J, Kleiter I, Kümpfel T.

Ther Clin Risk Manag. 2013;9:361-9. doi: 10.2147/TCRM.S41552. Epub 2013 Oct 3. Review.

13.

[[Natalizumab therapy, 2013].

Karácsony M, Bencsik K, Vécsei L.

Ideggyogy Sz. 2014 Jul 30;67(7-8):220-8. Review. Hungarian.

PMID:
25509362
15.

[Natalizumab in the treatment of multiple sclerosis].

Horga A, Horga de la Parte JF.

Rev Neurol. 2007 Sep 1-15;45(5):293-303. Review. Spanish.

16.

Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.

Hunt D, Giovannoni G.

Pract Neurol. 2012 Feb;12(1):25-35. doi: 10.1136/practneurol-2011-000092. Review.

PMID:
22258169
17.

Natalizumab for relapsing-remitting multiple sclerosis.

Horga A, Tintoré M.

Neurologia. 2011 Jul-Aug;26(6):357-68. doi: 10.1016/j.nrl.2010.10.004. Epub 2010 Dec 28. Review. English, Spanish.

18.

Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.

Warnke C, von Geldern G, Markwerth P, Dehmel T, Hoepner R, Gold R, Pawlita M, Kümpfel T, Mäurer M, Stangel M, Wegner F, Hohlfeld R, Straeten V, Limmroth V, Weber T, Hermsen D, Kleinschnitz C, Hartung HP, Wattjes MP, Svenningson A, Major E, Olsson T, Kieseier BC, Adams O.

Ann Neurol. 2014 Dec;76(6):792-801. doi: 10.1002/ana.24153. Epub 2014 May 8.

19.
20.

Natalizumab for relapsing remitting multiple sclerosis.

Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007621. doi: 10.1002/14651858.CD007621.pub2. Review.

PMID:
21975773

Supplemental Content

Support Center